FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula 1:
or pharmaceutically acceptable salts thereof, where values of Cy1; Cy2; L1; L2, R; R1; Rx and Ry and R2 are given in claim 1.
EFFECT: compounds are suitable for use as Raf protein kinase inhibitors.
36 cl, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CHROMENE DERIVATIVES | 2011 |
|
RU2574164C2 |
| N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | 2010 |
|
RU2553681C2 |
| COMBINED TREATMENT OF MALIGNANT NEOPLASM USING SULPHONAMIDE COMPOUND AND IMMUNOREGULATOR | 2020 |
|
RU2820817C2 |
| HETEROARYL COMPOUNDS AND USING THEM | 2009 |
|
RU2536584C2 |
| COMBINATION OF MCL-1 INHIBITOR AND TAXANE COMPOUND, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2763544C2 |
| INHIBITORS OF PROTEASE OF HEPATITIS C VIRUS AND THEIR APPLICATION | 2008 |
|
RU2515318C2 |
| SUBSTANCES PROVIDING PROTEIN DEGRADATION AND USE THEREOF | 2018 |
|
RU2830281C1 |
| QUINAZOLINE EFFECTIVE AS ION CHANNEL MODULATORS | 2005 |
|
RU2440991C2 |
| 4-AMINOQUINAZOLINE ANTAGONISTS OF SELECTIVE SODIUM AND CALCIUM ION CHANNELS | 2004 |
|
RU2378260C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
Authors
Dates
2013-09-10—Published
2008-06-30—Filed